The treatment led to a significant decrease in the COPD Assessment Test (CAT) and levels of high-mobility group box 1 (HMGB1), as well as high-sensitive C-reactive protein (hs CRP) in both groups. This evidence concerns the gene MAP3K14 and chronic obstructive pulmonary disease.